Prudential Financial Inc. Decreases Stock Holdings in Organon & Co. (NYSE:OGN)

Prudential Financial Inc. lessened its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 10.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 581,171 shares of the company's stock after selling 68,388 shares during the period. Prudential Financial Inc. owned 0.23% of Organon & Co. worth $8,671,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock valued at $453,593,000 after buying an additional 218,165 shares in the last quarter. Napatree Capital LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at $445,000. LPL Financial LLC lifted its holdings in Organon & Co. by 160.7% during the 4th quarter. LPL Financial LLC now owns 457,687 shares of the company's stock worth $6,829,000 after purchasing an additional 282,150 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Organon & Co. in the 4th quarter worth about $812,000. Finally, American Century Companies Inc. grew its holdings in Organon & Co. by 4.3% during the 4th quarter. American Century Companies Inc. now owns 42,948 shares of the company's stock valued at $641,000 after buying an additional 1,777 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Organon & Co. presently has an average rating of "Hold" and an average price target of $20.80.

Remove Ads

Organon & Co. Price Performance

NYSE:OGN traded down $0.30 during mid-day trading on Thursday, reaching $14.42. The stock had a trading volume of 522,395 shares, compared to its average volume of 3,263,960. The stock has a market capitalization of $3.72 billion, a P/E ratio of 4.33, a P/E/G ratio of 0.90 and a beta of 0.76. The firm has a 50 day moving average price of $15.26 and a two-hundred day moving average price of $16.12. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a one year low of $13.87 and a one year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. As a group, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.77%. Organon & Co.'s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.